Free Trial
NASDAQ:PRME

Prime Medicine (PRME) Stock Price, News & Analysis

Prime Medicine logo
$5.39 +0.40 (+8.02%)
As of 04:00 PM Eastern

About Prime Medicine Stock (NASDAQ:PRME)

Advanced

Key Stats

Today's Range
$4.82
$5.44
50-Day Range
N/A
52-Week Range
$1.11
$5.44
Volume
4.44 million shs
Average Volume
2.62 million shs
Market Capitalization
$725.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prime Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

PRME MarketRank™: 

Prime Medicine scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Prime Medicine.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prime Medicine is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prime Medicine is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prime Medicine has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    20.39% of the float of Prime Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Prime Medicine has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Prime Medicine has recently increased by 4.79%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Prime Medicine does not currently pay a dividend.

  • Dividend Growth

    Prime Medicine does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.39% of the float of Prime Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Prime Medicine has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Prime Medicine has recently increased by 4.79%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Prime Medicine has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Manufacturing companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Prime Medicine this week, compared to 6 articles on an average week.
  • Search Interest

    23 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Prime Medicine insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.74% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prime Medicine's insider trading history.
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRME Stock News Headlines

Comparing Vor Biopharma (NASDAQ:VOR) and Prime Medicine (NASDAQ:PRME)
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
Analyzing Prime Medicine (NASDAQ:PRME) and Vor Biopharma (NYSE:VOR)
Comparing Prime Medicine (NASDAQ:PRME) and Vor Biopharma (NYSE:VOR)
See More Headlines

PRME Stock Analysis - Frequently Asked Questions

Prime Medicine's stock was trading at $3.12 at the beginning of 2025. Since then, PRME stock has increased by 69.9% and is now trading at $5.30.

Prime Medicine (PRME) raised $175 million in an initial public offering on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share.

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Structure Therapeutics (GPCR), Black Diamond Therapeutics (BDTX), Bicycle Therapeutics (BCYC), BioCryst Pharmaceuticals (BCRX), atai Life Sciences (ATAI), Arrowhead Pharmaceuticals (ARWR) and Amesite (AMST).

Company Calendar

Today
9/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic Substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRME
Previous Symbol
NASDAQ:PRME
CIK
1894562
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
2019

Profitability

EPS (Trailing Twelve Months)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$195.88 million
Net Margins
-4,016.83%
Pretax Margin
-4,016.83%
Return on Equity
-156.16%
Return on Assets
-64.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.56
Quick Ratio
3.56

Sales & Book Value

Annual Sales
$2.98 million
Price / Sales
222.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.17 per share
Price / Book
4.21

Miscellaneous

Outstanding Shares
134,570,000
Free Float
103,972,000
Market Cap
$663.43 million
Optionable
N/A
Beta
2.39

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PRME) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners